{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:29:26Z","timestamp":1792441766713,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Dalbavancin, a lipoglycopeptide with a half-life of 150\u2013200 h, is a promising treatment option for prosthetic joint infections (PJIs) and other orthopaedic implant-associated infections (IAIs) caused by multidrug-resistant staphylococci. However, in vitro studies have shown that when exposed to low concentrations of dalbavancin, staphylococcal strains resistant to dalbavancin can emerge, potentially affecting its effectiveness in cases of recurrent infection. To investigate whether dalbavancin-resistant staphylococci emerge in vivo following long-term dalbavancin treatment for PJIs or orthopaedic IAIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Nineteen patients who had received long-term dalbavancin treatment (\u226512\u2005weeks) following PJI or orthopaedic IAI and 25 control patients scheduled for elective prosthetic joint surgery were sampled from the nares and perineum. Each sample was subcultured on Mueller\u2013Hinton II agar plates containing various concentrations of dalbavancin (0.0, 0.125, 0.5, and 2.0\u2005mg\/L). The growth of staphylococcal colonies was analysed using MALDI-TOF, and the MIC values of dalbavancin were determined using the gradient test method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among dalbavancin-treated patients, 4 out of 19 displayed staphylococcal species resistant to dalbavancin (MIC value &amp;gt;0.25\u2005mg\/L according to EUCAST breakpoint tables). These four were all Staphylococcus epidermidis isolates, three from the nares and one from the perineum, and displayed MIC values of 0.38, 0.38, 0.5, and 0.75\u2005mg\/L. No resistant staphylococci were detected in the samples from the control group (P\u200a=\u200a0.029, Fisher's exact test).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The present study demonstrated the emergence of dalbavancin-resistant staphylococci following long-term treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag218","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:34:58Z","timestamp":1781004898000},"source":"Crossref","is-referenced-by-count":2,"title":["Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections"],"prefix":"10.1093","volume":"81","author":[{"given":"Ronja","family":"Hugg","sequence":"first","affiliation":[{"name":"School of Medical Sciences, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro ,","place":["Sweden"]},{"name":"Department of Orthopedics, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Stegger","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro ,","place":["Sweden"]},{"name":"Department of Sequencing and Bioinformatics, Statens Serum Institut , Copenhagen ,","place":["Denmark"]},{"name":"Antimicrobial Resistance and Infectious Diseases Laboratory, Harry Butler Institute, Murdoch University , Perth ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5939-2932","authenticated-orcid":false,"given":"Bo","family":"S\u00f6derquist","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro ,","place":["Sweden"]},{"name":"Department of Orthopedics, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"2026062906224463000_dkag218-B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106960","article-title":"Expert opinion on dose regimen and therapeutic drug monitoring for long-term use of dalbavancin: expert review panel","volume":"62","author":"Senneville","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026062906224463000_dkag218-B2","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1097\/CORR.0000000000001838","article-title":"What are the long-term outcomes of mortality, quality of life, and hip function after prosthetic joint infection of the hip? A 10-year follow-up from Sweden","volume":"479","author":"Wildeman","year":"2021","journal-title":"Clin Orthop"},{"key":"2026062906224463000_dkag218-B3","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMoa2020198","article-title":"Antibiotic therapy for 6 or 12\u2005weeks for prosthetic joint infection","volume":"384","author":"Bernard","year":"2021","journal-title":"N Engl J Med"},{"key":"2026062906224463000_dkag218-B4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.diagmicrobio.2019.01.006","article-title":"Microbiology of polymicrobial prosthetic joint infection","volume":"94","author":"Flurin","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026062906224463000_dkag218-B5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.cmi.2021.06.006","article-title":"Microbiology of hip and knee periprosthetic joint infections: a database study","volume":"28","author":"Tai","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2026062906224463000_dkag218-B6","doi-asserted-by":"publisher","DOI":"10.1099\/mgen.0.000504","article-title":"Comparative genomics of Staphylococcus epidermidis from prosthetic-joint infections and nares highlights genetic traits associated with antimicrobial resistance, not virulence","volume":"7","author":"M\u00e5nsson","year":"2021","journal-title":"Microb Genomics"},{"key":"2026062906224463000_dkag218-B7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.diagmicrobio.2016.05.009","article-title":"In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections","volume":"85","author":"Fern\u00e1ndez","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026062906224463000_dkag218-B8","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10096-016-2845-z","article-title":"Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)","volume":"36","author":"Knafl","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026062906224463000_dkag218-B9","author":"Durata Therapeutics, Inc"},{"key":"2026062906224463000_dkag218-B10","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11080996","article-title":"Population pharmacokinetic and pharmacodynamic analysis of dalbavancin for long-term treatment of subacute and\/or chronic infectious diseases: the major role of therapeutic drug monitoring","volume":"11","author":"Cojutti","year":"2022","journal-title":"Antibiotics (Basel, Switzerland)"},{"key":"2026062906224463000_dkag218-B11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40262-021-01088-w","article-title":"Clinical pharmacokinetics and pharmacodynamics of dalbavancin","volume":"61","author":"Molina","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2026062906224463000_dkag218-B12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/jac\/dkac434","article-title":"Emerging resistance in Staphylococcus epidermidis during dalbavancin exposure: a case report and in vitro analysis of isolates from prosthetic joint infections","volume":"78","author":"Al Janabi","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026062906224463000_dkag218-B13","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae163","article-title":"Dalbavancin-resistant Staphylococcus epidermidis in vivo selection following a prosthetic joint infection: phenotypic and genomic characterization","volume":"6","author":"Ruffier d\u2019Epenoux","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2026062906224463000_dkag218-B14","doi-asserted-by":"publisher","DOI":"10.1099\/mgen.0.000744","article-title":"Hackflex: low-cost, high-throughput, Illumina Nextera Flex library construction","volume":"8","author":"Gaio","year":"2022","journal-title":"Microb Genom"},{"key":"2026062906224463000_dkag218-B15","doi-asserted-by":"publisher","first-page":"910.e1","DOI":"10.1016\/j.cmi.2020.08.025","article-title":"Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus","volume":"27","author":"Werth","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2026062906224463000_dkag218-B16","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/jac\/dkz562","article-title":"Occurrence of cross-resistance and \u03b2-lactam seesaw effect in glycopeptide-, lipopeptide- and lipoglycopeptide-resistant MRSA correlates with membrane phosphatidylglycerol levels","volume":"75","author":"Hines","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026062906224463000_dkag218-B17","doi-asserted-by":"crossref","first-page":"688357","DOI":"10.3389\/fmolb.2021.688357","article-title":"Synergy between beta-lactams and lipo-, glyco-, and lipoglycopeptides, is independent of the seesaw effect in methicillin-resistant Staphylococcus aureus","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2026062906224463000_dkag218-B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2023.116132","article-title":"Case report: prosthetic aortic valve endocarditis due to Staphylococcus epidermidis with acquired resistance in the walK gene","volume":"108","author":"Cepeda","year":"2024","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026062906224463000_dkag218-B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41426-018-0205-z","article-title":"Emergence of a dalbavancin induced glycopeptide\/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis","volume":"7","author":"Kussmann","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"2026062906224463000_dkag218-B20","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/cid\/ciac341","article-title":"Emergence of dalbavancin, vancomycin, and daptomycin nonsusceptible Staphylococcus aureus in a patient treated with dalbavancin: case report and isolate characterization","volume":"75","author":"Zhang","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026062906224463000_dkag218-B21","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae063","article-title":"The MIC distribution of dalbavancin differs between different coagulase-negative staphylococci","volume":"6","author":"Svensson","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2026062906224463000_dkag218-B22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/ddr.21466","article-title":"Antibiotics as both friends and foes of the human gut microbiome: the microbial community approach","volume":"80","author":"Nogueira","year":"2019","journal-title":"Drug Dev Res"},{"key":"2026062906224463000_dkag218-B23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5194\/jbji-9-191-2024","article-title":"Emergence of rifampicin-resistant staphylococci on the skin and nose of rifampicin-treated patients with an orthopaedic-device-related infection","volume":"9","author":"Wallimann","year":"2024","journal-title":"J Bone Jt Infect"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/7\/dkag218\/68643164\/dkag218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/7\/dkag218\/68643164\/dkag218.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:22:49Z","timestamp":1782728569000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag218\/8721458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag218","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,3]]},"article-number":"dkag218"}}